Liver Cancer In The Middle East

This book aims to illuminate the causes, incidence, and treatments of Hepatocellular Carcinoma(HCC) or liver cancer in the politically important and societally diverse region of the Middle East. Taking a flexible and inclusive view, it examines the influences of geography, crops and diet, ethnicity, and local behavior on both diagnosis and outcomes of this disease. Understanding the different causes of liver cancer enables effective strategies for both prevention and early diagnosis while knowledge of the different treatment modalities, their uses and limitations, availability and costs, works to inform rational treatment provision and selection. Divided into four sections, this book considers the causes and clinical syndromes associated with HCC, provides a detailed overview of clinical HCC and treatment modalities, describes country-specific clinical HCC experience and practice, and considers future needs and the potential for HCC collaborations across the region. Liver Cancer in the Middle East is a useful resource for clinicians seeking insight into the second highest cause of death from cancer worldwide, governments planning social and medical services for their peoples, as well as for international aid agencies prioritizing donations.

Cancer is low or absent on the health agendas of low- and middle-income countries (LMCs) despite the fact that more people die from cancer in these countries than from AIDS and malaria combined. International health organizations, bilateral aid agencies, and major foundations—which are instrumental in setting health priorities—also have largely ignored cancer in these countries. This book identifies feasible, affordable steps for LMCs and their international partners to begin to reduce the cancer burden for current and future generations. Stemming the growth of cigarette smoking tops the list to prevent cancer and all the other major chronic diseases. Other priorities include infant vaccination against the hepatitis B virus to prevent liver cancers and vaccination to prevent cervical cancer. Developing and increasing capacity for cancer screening and treatment of highly curable cancers (including most childhood malignancies) can be accomplished using "resource-level appropriateness" as a guide. And there are ways to make inexpensive oral morphine available to ease the pain of the many who will still die from cancer.

Strategic health planning, the cornerstone of initiatives designed to achieve health improvement goals around the world, requires an understanding of the comparative burden of diseases and injuries, their corresponding risk factors and the likely effects of invervention options. The Global Burden of Disease framework, originally published in 1990, has been widely adopted as the preferred method for health accounting and has become the standard to guide the setting of health research priorities. This publication sets out an updated assessment of the situation, with an analysis of trends observed since 1990 and a chapter on the sensitivity of GBD estimates to various sources of uncertainty in methods and data.

This atlas illustrates the latest available data on the cancer epidemic, showing causes, stages of development, and prevalence rates of different types of cancers by gender, income group, and region. It also examines the cost of the disease, both in terms of health care and commercial interests, and the steps being taken to curb the epidemic, from research and screening to cancer management programs and health education.

This book emphasizes the clinical epidemiology of chronic liver diseases with a specific focus on the methodology of the discussed studies. The whole spectrum of liver diseases is covered, from chronic hepatitis B and C, to hepatocellular carcinoma, alcoholic and non-alcoholic fatty liver diseases and autoimmune and cholestatic liver diseases. Readers will find the most up-to-date information on clinical epidemiology of hepatology, and will also be able to learn about important methodology and biostatistics information. Each chapter contains a summary table at the end of each chapter that highlights the most relevant landmark studies, their main outcomes and the unique features of the methodology. The book will appeal to both practicing clinicians as well as clinical research investigators. In addition, this would likely be of interest to medical school or public health school students to learn about hepatology epidemiology, but also some specific fundamentals of clinical research and clinical epidemiology.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Since the Iraq war, the Middle East has been in continuous upheaval, resulting in the displacement of millions of people. Arriving from Afghanistan, Iraq, Palestine, and Syria in other parts of the world, the refugees show remarkable resilience and creativity amidst profound adversity. Through careful ethnography, this book vividly illustrates how refugees navigate regimes of exclusion, including cumbersome bureaucracies, financial insecurities, medical challenges, vilifying stereotypes, and threats of violence. The collection bears witness to their struggles, while also highlighting their aspirations for safety, settlement, and social inclusion in their host societies and new homes.

This book, in a new, extensively updated edition, covers viral infection, virus-induced inflammation and tissue injuries, viral epidemiology, oncogenic mechanisms, and current and emerging preventive and therapeutic strategies in detail. Readers will also find information on the individual aspects of a number of oncogenic viruses, including hepatitis B, hepatitis C, human papillomavirus, Epstein–Barr virus, human T-cell lymphotropic virus, Kaposi sarcoma-associated herpes, and Merkel cell polyomavirus, as well as associated human cancers. The book will benefit all those who are seeking a comprehensive, up-to-date overview of the basic and clinical aspects of oncogenic viruses and associated human cancers. Following its original publication in 2014, the first edition of this book quickly became an influential text in the field. This second edition duly reflects the significant advances in knowledge and research that have been achieved in the years since.